ZIRGAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZIRGAN (ZIRGAN).
Ganciclovir is a synthetic guanine derivative that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) and by incorporating into viral DNA, causing chain termination. Ganciclovir is phosphorylated to ganciclovir triphosphate by viral thymidine kinase (UL97) in CMV-infected cells.
| Metabolism | Ganciclovir is not significantly metabolized; it is eliminated primarily by renal excretion via glomerular filtration and active tubular secretion. |
| Excretion | Primarily renal excretion as unchanged drug via glomerular filtration and tubular secretion; >90% of a systemically absorbed dose is recovered unchanged in urine. |
| Half-life | Terminal elimination half-life in patients with normal renal function is approximately 3-4 hours; in renal impairment, half-life may be prolonged up to 30 hours, requiring dose adjustment. |
| Protein binding | <1% bound to plasma proteins. |
| Volume of Distribution | 0.2-0.3 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Not applicable for topical ophthalmic route; systemic bioavailability is negligible (<0.1%). |
| Onset of Action | Not applicable for topical ophthalmic administration; systemic absorption is minimal and no clinical onset data is relevant. |
| Duration of Action | Therapeutic effect duration corresponds to dosing interval (5 times daily); no prolonged duration due to rapid elimination. |
Instill 1 drop (approximately 0.05 mL) into affected eye(s) 5 times daily (approximately every 3 hours while awake) until corneal ulcer heals, then reduce to 1 drop 3 times daily for 7 days.
| Dosage form | GEL |
| Renal impairment | No systemic absorption anticipated; no dosage adjustment required for renal impairment. |
| Liver impairment | No systemic absorption anticipated; no dosage adjustment required for hepatic impairment based on Child-Pugh classification. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no specific weight-based dosing guidelines available. |
| Geriatric use | No specific dosage adjustment recommended; use same dosing as adults, with monitoring for tolerability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZIRGAN (ZIRGAN).
| Breastfeeding | No data on excretion in human milk. M/P ratio unknown. Systemic absorption after ophthalmic use is minimal, but caution advised. Consider risk to infant of ganciclovir exposure versus benefit of breastfeeding. |
| Teratogenic Risk | FDA Pregnancy Category C. Animal studies show embryotoxicity and teratogenicity (skeletal abnormalities) at systemic exposures similar to human doses. No adequate human studies. First trimester: potential risk of major malformations; second and third trimesters: risk of fetal toxicity including low birth weight and developmental delay. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
Granulocytopenia, anemia, and thrombocytopenia; animal studies have shown carcinogenicity and teratogenicity; rapid infusion may cause increased serum creatinine.
| Serious Effects |
Hypersensitivity to ganciclovir or acyclovir; absolute neutrophil count < 500 cells/μL; platelet count < 25,000/μL.
| Precautions | Hematologic toxicity: neutropenia, anemia, thrombocytopenia; renal impairment: dose adjustment required; potential for mutagenicity and carcinogenicity; use in pregnancy only if benefit outweighs risk; may cause fetal harm; monitor renal function and blood counts. |
Loading safety data…
| Fetal Monitoring | Monitor intraocular pressure, visual acuity, and slit-lamp examination monthly. Systemic ganciclovir monitoring not required due to minimal absorption. Fetal monitoring via ultrasound if maternal systemic exposure is suspected (e.g., accidental ingestion). |
| Fertility Effects | Animal studies indicate reduced fertility and sperm abnormalities in males (ganciclovir causes testicular toxicity). Females: may cause decreased implantation and increased preimplantation loss. Human data limited; advise contraception during use. |